Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis

International Journal of Cancer

Volumn 137, Issue 8, 2015, Pages 1931-1937

  Ogilvie, Gina S ^a,b   Naus, Monika ^a,b   Money, Deborah M ^a,c   Dobson, Simon R ^a,d   Miller, Dianne ^a,e   Krajden, Mel ^a,b   Van Niekerk, Dirk J ^e   Coldman, Andrew J ^e  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^c CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

^d BC CHILDREN S HOSPITAL   (Canada)

^e BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

cervical intraepithelial neoplasia; HPV vaccine; human papillomavirus; primary cancer prevention; vaccination program

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CANADA; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; POPULATION RESEARCH; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; RISK REDUCTION; RURAL AREA; TREND STUDY; UTERINE CERVIX CARCINOMA IN SITU; YOUNG ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; PAPILLOMAVIRUS INFECTIONS; REGRESSION ANALYSIS; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ADOLESCENT; ADULT; BRITISH COLUMBIA; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; REGRESSION ANALYSIS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84938949949     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29508     Document Type: Article

References (23)

1. Kjaer SK, Sigurdsson K, Iversen OE, et al., A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res 2009; 2: 868 -8 78.
2. Munoz N, Kjaer SK, Sigurdsson K, et al., Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010; 102: 325 -3 39.
3. Dillner J, Kjaer SK, Wheeler CM, et al., Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010; 341: c3493
4. Paavonen J, Naud P, Salmeron J, et al., Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374: 301-314.
5. Lehtinen M, Paavonen J, Wheeler CM, et al., Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13: 89-99.
6. Markowitz LE, Hariri S, Unger ER, et al., Post-licensure monitoring of HPV vaccine in the United States. Vaccine 2010; 28: 4731-4737.
7. Fairley CK, Hocking JS, Gurrin LC, et al., Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009; 85: 499-502.
8. Brotherton JM, Fridman M, May CL, et al., Early effect of the HPV vaccination programme on cervical abnormalities in victoria, australia: an ecological study. Lancet 2011; 377: 2085-2092.
9. Howell-Jones R, Soldan K, Wetten S, et al., Declining genital warts in young women in england associated with HPV 16/18 vaccination: an ecological study. J InfectDis 2013; 208: 1397 -1 403.
10. Ali H, Donovan B, Wand H, et al., Genital warts in young australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013; 346: f2032
11. Markowitz LE, Hariri S, Lin C, et al., Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the united states, national health and nutrition examination surveys, 2003-2010. J InfectDis 2013;208: 385-393.
12. National Advisory Committee on Immunization (NACI). Update on human papillomavirus Vaccines. Canada Communicable Disease Report-‰=-‰Releve Des Maladies Transmissibles Au Canada 2012; 38: 1-62.
13. Ogilvie GS, Remple VP, Marra F, et al., Parental intention to have daughters receive the human papillomavirus vaccine. Can Med Assoc J 2007; 177: 1506
14. Ogilvie GS, Remple VP, Marra F, et al., Intention of parents to have male children vaccinated with the HPV vaccine. Sex Transm Infect 2008; 318 -3 23.
15. BC Centre for Disease Control Immunzation Program. Immunization Coverage Rates, British Columbia. British Columbia Centre for Disease Control 2013; www.bccdc.org.
16. Ogilvie G, Anderson M, Marra F, et al., A Population-based evaluation of a publicly funded, School-based HPV vaccine program in british columbia, canada: parental factors associated with HPV vaccine receipt. PLoS Med 2010; 7: e1000270
17. Ogilvie GS, Taylor DL, Achen M, et al., Self-collection of genital human papillomavirus specimens in heterosexual men. Sex Transm Infect 2009; 85: 221-225.
18. Ogilvie GS, Cook DA, Taylor DL, et al., Population-based evaluation of type-specific HPV prevalence among women in british columbia, canada. Vaccine 2013; 31: 1129-33.
19. Krajden M, Karunakaran K, So S, et al., Prevalence of human papillomavirus 16 and 18 neutralizing antibodies in prenatal women in british columbia. ClinVaccine Immunol 2009; 16: 1840-1843.
20. BC Cancer Agency Cervical Cancer Screening Program Annual Report, 2012 Vancouver, BC, 2012.
21. Gunther OP, Ogilvie G, Naus M, et al., Protecting the next generation: what is the role of the duration of human papillomavirus vaccine-related immunity?. J Infect Dis 2008; 197: 1653-1661.
22. Quinn M, Babb P, Jones J, et al., Effect of screening on incidence of and mortality from cancer of cervix in england: evaluation based on routinely collected statistics. BMJ 1999; 318: 904-908.
23. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-1927.